Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...

Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

Discover OPKO Health's Q2 2025 earnings insights, highlighting asset sales, cost savings, and pipeline advancements.

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

Present results of the TACTIVE-N trial, a Phase 2 clinical trial of neoadjuvant vepdegestrant, in a mini oral session at European Society for Medical Oncology 2025 Congress (ClinicalTrials.gov ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

Summit Biotech Fund backs opportunities in the ASX healthcare space and sees upside in three particular names including ...